Consolidated Statement of Cash Flows	12 Months Ended
	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Cash flows from operating activities:
Net loss	$ (21,310,000)	$ (36,732,000)	$ (39,615,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	1,120,000	427,000	3,371,000
Change in fair value of contingent consideration liability	(27,132,000)	(8,149,000)	39,913,000
Recognition of right to borrow asset			(2,800,000)
Amortization of debt discount and deferred interest	2,246,000	2,216,000	1,079,000
Amortization of discount on available-for-sale securities	81,000	163,000
Depreciation and amortization	3,001,000	3,393,000	3,323,000
Loss/(gain) on disposal of property and equipment		8,000	(15,000)
Impairment of property and equipment	8,591,000	0
Impairment of inventory	1,229,000
Impairment of prepaid expenses	1,024,000
Changes in operating assets and liabilities:
Receivables	173,000	(44,000)	(129,000)
Inventory	2,500,000	(282,000)	(3,447,000)
Prepaid expenses and other current assets	(1,152,000)	(822,000)	(601,000)
Other assets	1,812,000
Accounts payable	(1,357,000)	(1,990,000)	1,642,000
Accrued clinical trial expense and other accrued liabilities	558,000	654,000	1,122,000
Deferred revenues	(2,665,000)	413,000	(2,916,000)
Other liabilities	(602,000)	(754,000)	(1,539,000)
Net cash used in operating activities	(31,883,000)	(41,499,000)	(612,000)
Cash flows from investing activities:
Purchase of available-for-sale securities	(5,796,000)	(42,003,000)	(19,227,000)
Maturities of available-for-sale securities	25,292,000	30,840,000	10,650,000
Purchases of property and equipment	(58,000)	(2,363,000)	(1,784,000)
Proceeds from disposal of property and equipment	15,000		16,000
Net cash (used in) provided by investing activities	19,453,000	(13,526,000)	(10,345,000)
Cash flows from financing activities:
Proceeds from issuance of common stock, common stock warrants and exercise of stock options and stock purchase rights	182,000	5,878,000	6,583,000
Payment of contingent payment to Symphony Allegro Holdings, LLC	(868,000)	(251,000)	(10,313,000)
Change in restricted cash	2,757,000	(2,757,000)	5,051,000
Proceeds from financing obligations	2,914,000	50,830,000	15,000,000
Payments of financing obligations		(781,000)	(5,773,000)
Net cash provided by financing activities	4,985,000	52,919,000	10,548,000
Net decrease in cash and cash equivalents	(7,445,000)	(2,106,000)	(409,000)
Cash and cash equivalents at beginning of period	15,200,000	17,306,000
Cash and cash equivalents at end of period	7,755,000	15,200,000	17,306,000
Supplemental disclosures of cash flow information
Cash paid for interest	$ 2,757,000	4,169,000	863,000
Non cash investing and financing activities:
Debt discount related to Teva Note			4,405,000
Value of warrants issued with royalty securitization financing		1,721,000
Value of the beneficial conversion feature related to borrowing against Teva Note		$ 1,032,000	3,112,000
Value of right to borrow asset reclassified as debt discount			$ 2,800,000